Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .
A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .
For the treatment of recurrent or metastatic squamous cell head and neck cancer .
For the treatment of recurrent ovarian cancer .
For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .
For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Conditions
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 208
- Registration Number
- NCT01835236
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 150
- Registration Number
- NCT01730677
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 15
- Registration Number
- NCT01687439
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
- Conditions
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 8
- Registration Number
- NCT01683682
- Locations
- 🇩🇪
Klinikum Kassel GmbH, Kassel, Germany
🇩🇪Krankenhaus Großhansdorf, Großhansdorf, Germany
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)
- Conditions
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 7
- Registration Number
- NCT01684111
- Locations
- 🇩🇪
Klinikum der Universität München, München, Germany
🇩🇪Klinikum Kassel GmbH, Kassel, Hessen, Germany
🇩🇪Thoraxklinik Universitätsklinikum Heidelberg, Heidelberg, Germany
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2016-10-20
- Target Recruit Count
- 94
- Registration Number
- NCT01683175
- Locations
- 🇨🇳
The affiliated hospital of medical college Qingdao University, Qingdao, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳The third affiliated hospital of Harbin Medical Univer, Harbin, China
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 213
- Registration Number
- NCT01565083
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 139
- Registration Number
- NCT01520103
- Locations
- 🇩🇪
Hämatologisch-onkologische Gemeinschaftspraxis, Münster, Münster, Germany
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Eugene Hwang
- Target Recruit Count
- 13
- Registration Number
- NCT01497860
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT01441596
- Locations
- 🇰🇷
1200.67.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇺🇸1200.67.10105 Boehringer Ingelheim Investigational Site, Fullerton, California, United States
🇺🇸1200.67.10108 Boehringer Ingelheim Investigational Site, Santa Barbara, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.